We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.97B
AUM Growth
-$817M
Cap. Flow
-$41.1M
Cap. Flow %
-0.52%
Top 10 Hldgs %
77.13%
Holding
94
New
12
Increased
15
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$71.2M
2
BCYC
Bicycle Therapeutics
BCYC
+$67M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$43.3M
4
ABCL icon
AbCellera Biologics
ABCL
+$23.6M
5
DNLI icon
Denali Therapeutics
DNLI
+$21.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$242M
2
IMCR icon
Immunocore
IMCR
+$69M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$20.9M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$14.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.5B
$2.06B 25.86%
36,179,665
+543
+0% +$32.6K
ONC
2
BeOne Medicines Ltd
ONC
$34.2B
$1.65B 20.73%
10,568,897
– –
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.52B
$793M 9.94%
42,864,612
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.6B
$526M 6.6%
1,969,798
– –
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.42B
$277M 3.48%
6,398,365
– –
RVMD icon
6
Revolution Medicines
RVMD
$39.1B
$243M 3.05%
7,549,249
+2,400,592
+47% +$71.2M
KYMR icon
7
Kymera Therapeutics
KYMR
$8.88B
$241M 3.02%
5,995,928
– –
ABCL icon
8
AbCellera Biologics
ABCL
$1.69B
$125M 1.56%
27,525,640
+4,615,887
+20% +$23.6M
BCYC
9
Bicycle Therapeutics
BCYC
$274M
$123M 1.54%
4,942,823
+3,152,433
+176% +$67M
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.38B
$107M 1.34%
5,840,059
+2,727,273
+88% +$43.3M
IMCR icon
11
Immunocore
IMCR
$1.71B
$98.5M 1.24%
1,515,318
-1,005,413
-40% -$69M
KOD icon
12
Kodiak Sciences
KOD
$2.59B
$91.1M 1.14%
17,310,490
– –
ROIV icon
13
Roivant Sciences
ROIV
$24B
$78.1M 0.98%
7,413,834
-179,190
-2% -$1.93M
REPL icon
14
Replimune Group
REPL
$463M
$78M 0.98%
9,545,336
– –
DNLI icon
15
Denali Therapeutics
DNLI
$3.86B
$76.6M 0.96%
3,731,695
+1,124,499
+43% +$21.1M
TRDA icon
16
Entrada Therapeutics
TRDA
$260M
$68.9M 0.86%
4,865,819
– –
AKRO
17
DELISTED
Akero Therapeutics
AKRO
$68.5M 0.86%
2,713,205
+344,827
+15% +$8.28M
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.5B
$68.5M 0.86%
1,466,547
– –
IMTX icon
19
Immatics
IMTX
$1.22B
$67.7M 0.85%
6,443,398
+604,545
+10% +$7.05M
CERE
20
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$67.6M 0.85%
1,600,000
– –
ARGX icon
21
argenx
ARGX
$55.3B
$59.5M 0.75%
151,215
– –
NRIX icon
22
Nurix Therapeutics
NRIX
$2.5B
$57.1M 0.72%
3,882,125
– –
KNSA icon
23
Kiniksa Pharmaceuticals
KNSA
$6.23B
$55.4M 0.7%
2,809,577
– –
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.47B
$51.4M 0.65%
10,126,176
– –
JBIO
25
Jade Biosciences
JBIO
$1.22B
$49.7M 0.62%
48,015
– –
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Baker Bros. Advisors held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
  • Baker Bros. Advisors's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
  • Baker Bros. Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
  • Baker Bros. Advisors opened 12 new positions and closed 7 in Q1 2024.
  • Baker Bros. Advisors's portfolio value fell 9.3% quarter-over-quarter to $7.97B.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.